作为神经退行症疾病修饰策略的NAD增强
Christian Dölle1, Charalampos Tzoulis1
1Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway; Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; K.G. Jebsen Center for Translational Research in Parkinson's Disease, University of Bergen, Pb 7804, 5020 Bergen, Norway.
Trends in endocrinology and metabolism: TEM
|April 26, 2025
概括
尼古丁胺胺氨基二核酸 (NAD) 增强显示了通过向关键途径来治疗神经退行性疾病的前景. 需要进一步的研究来优化NAD补充策略,以获得最大的治疗效益.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病 (NDD) 构成了日益严重的全球健康挑战,没有有效的疾病修饰疗法.
- NAD增强是一种新兴的策略,针对NDD的关键途径,包括线粒体功能障碍,能量缺陷,蛋白质稳定和神经炎症.
研究的目的:
- 讨论NDDs的NAD增强的逻辑和不断变化的治疗场景.
- 突出需要进行特定环境的研究,以优化NAD补充剂的疗效.
主要方法:
- 关于神经退行性疾病中NAD增强的当前文献的综述.
- 分析早期临床试验数据和正在进行的研究.
主要成果:
- 增强NAD的目标是多个关键疾病途径,涉及到NDDs.
- 一些临床试验正在进行中,这表明该领域的兴趣和进展显著.
结论:
- 增加NAD对神经退行性疾病具有治疗潜力.
- 识别特定的背景和解决知识差距对于实现NAD补充的全部潜力至关重要.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Long-term Potentiation
54.4K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
54.4K


